HUMA vs. ARQT, BHVN, SDGR, EWTX, JANX, ETNB, ADPT, DYN, SPRY, and EVO
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Arcutis Biotherapeutics (ARQT), Biohaven (BHVN), Schrödinger (SDGR), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), 89bio (ETNB), Adaptive Biotechnologies (ADPT), Dyne Therapeutics (DYN), ARS Pharmaceuticals (SPRY), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry.
Humacyte vs. Its Competitors
Humacyte (NASDAQ:HUMA) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
Humacyte has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500.
Arcutis Biotherapeutics received 29 more outperform votes than Humacyte when rated by MarketBeat users. However, 70.97% of users gave Humacyte an outperform vote while only 68.22% of users gave Arcutis Biotherapeutics an outperform vote.
Humacyte has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Arcutis Biotherapeutics' return on equity of -119.11% beat Humacyte's return on equity.
Humacyte presently has a consensus target price of $11.71, suggesting a potential upside of 378.13%. Arcutis Biotherapeutics has a consensus target price of $18.80, suggesting a potential upside of 38.85%. Given Humacyte's stronger consensus rating and higher probable upside, equities research analysts plainly believe Humacyte is more favorable than Arcutis Biotherapeutics.
In the previous week, Humacyte had 3 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 14 mentions for Humacyte and 11 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.93 beat Humacyte's score of 0.58 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.
Humacyte has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.
44.7% of Humacyte shares are owned by institutional investors. 5.1% of Humacyte shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Humacyte beats Arcutis Biotherapeutics on 13 of the 19 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Humacyte Competitors List
Related Companies and Tools
This page (NASDAQ:HUMA) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy HUMA Stock Free HUMA Stock Alerts